Diagnostic performance of host protein signatures as a triage test for active pulmonary TB

Author:

Koeppel Lisa1,Denkinger Claudia M.123ORCID,Wyss Romain2,Broger Tobias12,Chegou Novel N.4,Dunty Jill M.5,Scott Kerry5,Cáceres Tatiana6,Dutoit Elloise7,Ugarte-Gil Cesar68,Nicol Mark79,Gotuzzo Eduardo68,Corstjens Paul L. A. M.10,Geluk Annemieke11,Sutherland Jayne12,Sigal George B.5,Moreau Emmanuel2,Albertini Audrey2,Mantsoki Anna2,Ongarello Stefano2,Walzl Gerhard4,Fernandez Suarez Marta2

Affiliation:

1. Division of Infectious Disease and Tropical Medicine, University of Heidelberg , Heidelberg, Germany

2. FIND , Geneva, Switzerland

3. German Center for Infection Research (DZIF), Heidelberg University Hospital Partner Site , Heidelberg, Germany

4. DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University , Cape Town, South Africa

5. Meso Scale Diagnostics, LLC , Rockville, Maryland, USA

6. Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia , Lima, Peru

7. Division of Medical Microbiology at the University of Cape Town (UCT) , Cape Town, South Africa

8. School of Medicine, Universidad Peruana Cayetano Heredia (UPCH) , Lima, Peru

9. Division of Infection and Immunity, School of Biomedical Sciences, University of Western Australia , Perth, Australia

10. Department of Cell and Chemical Biology, Leiden University Medical Center , Leiden, the Netherlands

11. Department of Infectious Diseases, Leiden University Medical Center , Leiden, the Netherlands

12. TB Research Group, Vaccines and Immunity Theme, MRC Unit The Gambia at LSHTM , Banjul, Gambia

Abstract

ABSTRACT The current four-symptom screen recommended by the World Health Organization (WHO) is widely used as screen to initiate diagnostic testing for active pulmonary tuberculosis (TB), yet the performance is poor especially when TB prevalence is low. In contrast, more sensitive molecular tests are less suitable for placement at primary care level in low-resource settings. In order to meet the WHO End TB targets, new diagnostic approaches are urgently needed to find the missing undiagnosed cases. Proteomics-derived blood host biomarkers have been explored because protein detection technologies are suitable for the point-of-care setting and could meet cost targets. This study aimed to find a biomarker signature that fulfills WHO’s target product profile (TPP) for a TB screening. Twelve blood-based protein biomarkers from three sample populations (Vietnam, Peru, and South Africa) were analyzed individually and in combinations via advanced statistical methods and machine learning algorithms. The combination of I-309, SYWC and kallistatin showed the most promising results to discern active TB throughout the data sets meeting the TPP for a triage test in adults from two countries (Peru and South Africa). The top-performing individual markers identified at the global level (I-309 and SYWC) were also among the best-performing markers at country level in South Africa and Vietnam. This analysis clearly shows that a host protein biomarker assay is feasible in adults for certain geographical regions based on one or two biomarkers with a performance that meets minimal WHO TPP criteria.

Funder

Government of the Netherlands

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Reference36 articles.

1. World Health Organization . 2015. The end TB strategy. World Health Organization.

2. World Health Organization . 2021. WHO consolidated guidelines on tuberculosis: module 3: diagnosis - tests for tuberculosis infection. World health organization.

3. Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better?

4. Finding the Missing Patients With Tuberculosis: Lessons Learned From Patient-Pathway Analyses in 5 Countries

5. Correction: Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort study

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3